Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


ThromboGenics raises €35 million in its IPO on Eurolist by Euronext Brussels
And additionally €3.5 million in over-allotment shares will be allocated

Leuven, Belgium – 6th July, 2006 – ThromboGenics, a biopharmaceutical company focused on the development of novel medicines for the treatment of vascular disease, announced today that it has successfully completed its initial public offering (IPO) on the Eurolist by Euronext Brussels. Pursuant to the offering, 7,777,778 new shares, equivalent to €35 million, will be issued by ThromboGenics, and additionally, 777,778 over-allotment shares, equivalent to €3.5million will be allocated. The IPO price amounts to €4.50 per share. Shares will start trading as of 7th July on the Eurolist by Euronext Brussels under the symbol THR.

Commenting on today’s announcement, Professor Désiré Collen, CEO of ThromboGenics said: “We are delighted to have successfully completed our IPO and to have been able to secure the interest of high quality institutional investors. I view this positive outcome as a reflection of our strong equity story and investors’ confidence in ThromboGenics’ growth prospects. The funds raised will enable us to advance the development of our promising pipeline of products to address a broad range of conditions related to the vascular system, including back of the eye disease, stroke and peripheral vascular diseases.”

Offering highlights

  • The offering was 15% oversubscribed.
  • Placement of 7,777,778 new shares with VVPR strips at €4.50 per share, providing ThromboGenics with gross proceeds of €35 million. Together with the existing shares, the number of outstanding shares will be 22,140,305, representing a market capitalisation of approximately €100 million immediately after the IPO.
  • 20% of the total offering will be allocated to retail investors in Belgium and 80% to institutional investors across Europe.
  • Subscriptions of retail investors will be allocated a rato 100% for subscriptions up to 2,500 shares, and a rato 85% for subscriptions above 2,501 shares. Subscriptions of institutional investors will also be reduced.
  • KBC Securities acted as Lead Manager to the listing.
  • The Lead Manager is granted an over-allotment option, exercisable as of the first listing date until 30 days thereafter, to purchase additionally 777,778 shares at the IPO price. The shares covered by the over-allotment option are existing shares that will be lent by the Selling Shareholders to the Lead Manager and have no separate VVPR strip.
  • The shares and VVPR strips will be listed and traded on the Eurolist by Euronext Brussels as of 7th July on an “as if-and-when-issued” basis under the symbol THR (shares) and THRS (VVPR strips). Delivery and payment of the ThromboGenics shares will be made on 11th July 2006.
  • The current shareholders have entered into a lock-up period which will expire in 12 months from the first listing date. During the last six months of the lock-up period (the “soft” lock-up period), the lock-up obligations will, under certain conditions, not apply to an organised sale of shares in the Issuer.

    New independent director appointment
    On 4 July 2006, the shareholders’ meeting of ThromboGenics NV decided to revoke its decision de dato 7 June 2006 to appoint Herman Daems as independent director, upon his own request, and, subject to the same condition precedent of establishment of the capital increase in cash in association with the IPO, to appoint Luc Philips instead as new independent director.

    Luc Philips has a degree in commercial and financial sciences from the Hoger Instituut voor Bestuurs- en Handelswetenschappen (HIBH) in Brussels. In 1997, he was appointed to the board of directors and the executive committee of Kredietbank. From 1998 to 2003, he was managing director of the KBC Bank and Insurance Holding Company and KBC Bank. He was appointed managing director of Almanij in 2003. In the same year, he was also appointed director of the KBC Bank and Insurance Holding Company, KBC Bank, KBC Insurance and KBL, and became chairman of the audit committee of the first thr

    Publisher Contact Information:

    ThromboGenics Ltd.

    Company profile of ThromboGenics Ltd.
    Past press releases of ThromboGenics Ltd. .

  • Data

    Tech investments
    From our Online Data Service
    VC-backed companies
    From our Radar

    Recent Deals

    Nov 25€24.0MInternet commerce
    Nov 8N/AOther Computers & Electronics
    Nov 5€2.1MAudio/Video
    Nov 5€5.2MOther Computers & Electronics
    Nov 5€0.4MInternet services
    Nov 5€1.3MSecurity
    Nov 5€1.5MAudio/Video

    For information on Europe's most extensive database on technology funding click here!


    Press Releases

    Sep 30
    tetavi raises $6 million to help more companies bring 3d holograms ...

    May 28
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    nethone raised over $1 million from innovation nest

    Mar 31
    the fit allocates chf 100'000 to comppair technologies

    Jan 29
    yumpingo raises $10m to transform guest experiences in restaurants

    About usContact usLegal Information
    Copyright © 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.